## **Core Concept**
Vorapaxar is an antiplatelet medication that works by inhibiting platelet activation and aggregation. It specifically targets a key receptor involved in the platelet activation process.

## **Why the Correct Answer is Right**
Vorapaxar primarily acts by inhibiting the **thrombin receptor**, also known as protease-activated receptor-1 (PAR-1). This receptor is activated by thrombin, a potent serine protease that plays a critical role in coagulation and platelet activation. By blocking PAR-1, vorapaxar effectively reduces platelet aggregation caused by thrombin.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because vorapaxar's primary mechanism does not involve inhibition of ADP (adenosine diphosphate) receptors. ADP is another important substance that promotes platelet aggregation, but it acts through different receptors (P2Y12).
- **Option B:** This option is incorrect because vorapaxar does not primarily inhibit the action of prostaglandins or thromboxanes, which are involved in platelet activation but through different pathways.
- **Option C:** This option might seem plausible but is incorrect because vorapaxar specifically targets the thrombin receptor (PAR-1), not the collagen receptor.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that vorapaxar is used in the prevention of thrombotic events in patients with acute coronary syndrome (ACS) or peripheral artery disease (PAD), and it has a unique mechanism of action through PAR-1 inhibition. This mechanism distinguishes it from other antiplatelet drugs like clopidogrel, which inhibit the P2Y12 receptor.

## **Correct Answer:** D. Thrombin.